Overview

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness of paliperidone ER for the treatment of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants.

Phase:

Phase 4

Details

Lead Sponsor:

Johnson & Johnson Taiwan Ltd

Treatments:

Paliperidone Palmitate